Levosimendan Carinopharm

Levosimendan, the active ingredient in Levosimendan Carinopharm, is a calcium sensitizer / inodilator presented as an injectable solution for intravenous use. It treats acute decompensated heart failure and severe chronic heart failure in adult patients.

GNH USA supplies Levosimendan Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levosimendan is used in the management of heart failure, acting as a calcium sensitizer and vasodilator.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Severe chronic heart failure: provides hemodynamic support when standard therapy is insufficient. Heart failure with reduced ejection fraction (HFrEF): enhances myocardial contractility without increasing intracellular calcium.

Levosimendan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity during treatment. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate. - Atrial fibrillation: irregular heart rhythm. - Flushing: warm sensation and skin reddening.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Allergic reactions: rash, itching, or anaphylaxis. - Liver enzyme elevation: signs of hepatic stress. - Electrolyte disturbances: especially potassium shifts.

Levosimendan requires careful monitoring and specific safety measures.

Cardiovascular monitoring: observe blood pressure and heart rhythm continuously. Electrolyte balance: correct potassium and magnesium levels before infusion. Renal function: assess creatinine clearance, adjust therapy if impaired. Hepatic impairment: use with caution in patients with liver disease. Contraindications: avoid in severe hypotension, obstructive cardiomyopathy, or critical aortic stenosis. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify volume depletion and hypotension. - Beta‑blockers: can blunt the positive inotropic effect. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Anticoagulants: monitor for increased bleeding risk due to vasodilation.